Clinical Features, Treatment, and Outcome of HIV-Associated Immune Thrombocytopenia in the HAART Era
Table 2
Treatment regimens for HIV-associated ITP and responses achieved.
Treatment
Dose
N
Bleeding (%)
R + CR (%)
CR (%)
Median time to R in days (range)
Relapse (%)
IVIG
1 g/kg/day2 days
7
6 (86)
5 (71)
4 (57)
4 (3–9)
6 (86)
Anti-D
2.4–4 mg
7
2 (29)
6 (86)
0 (0)
14 (1–61)
4 (57)
Prednisone
50–85 mg daily
4
2 (50)
4 (100)
1 (25)
4.5 (3–13)
3 (75)
HAART alone
4
1 (25)
3 (75)
1 (25)
267 (1–1379)
3 (75)
IVIG +
1 g/kg/day2 days
5
4 (80)
5 (100)
3 (60)
11 (3–16)
3 (60)
Prednisone
50–70 mg
Anti-D +
1.3 mg
1
1 (100)
1 (100)
0 (0)
22
1 (100)
Prednisone
40 mg daily
HAART +
9
5 (56)
8 (89)
5 (56)
13.5 (3–22)
4 (44)
Other therapy
None
3
0 (0)
2 (67)
2 (67)
696 (26–3192)
2 (67)
*HAART was 1 nucleoside analog (NA), 1 protease inhibitor, and either a 2nd NA or a nonnucleoside reverse transcription inhibitor.
**Other therapy was IVIG, prednisone, or anti-D in the doses listed above. Patients in this group were also included in the groups above with patients who received the respective therapies without HAART.
